| __timestamp | CRISPR Therapeutics AG | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 18516000 |
| Thursday, January 1, 2015 | 12573000 | 34140000 |
| Friday, January 1, 2016 | 42238000 | 51872000 |
| Sunday, January 1, 2017 | 69800000 | 71772000 |
| Monday, January 1, 2018 | 113773000 | 97501000 |
| Tuesday, January 1, 2019 | 179362000 | 118590000 |
| Wednesday, January 1, 2020 | 266946000 | 169802000 |
| Friday, January 1, 2021 | 438633000 | 192507000 |
| Saturday, January 1, 2022 | 461645000 | 199563000 |
| Sunday, January 1, 2023 | 387332000 | 253598000 |
| Monday, January 1, 2024 | 320653000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, innovation is the lifeblood that propels companies forward. CRISPR Therapeutics AG and Xencor, Inc. are two such pioneers, each with a unique approach to research and development (R&D). Over the past decade, CRISPR Therapeutics has consistently outpaced Xencor in R&D spending, with a staggering 60% more investment on average. This trend is evident from 2014 to 2023, where CRISPR's R&D expenses surged from a modest $1.5 million to nearly $462 million in 2022, before slightly dipping in 2023. Meanwhile, Xencor's investment grew steadily, peaking at approximately $254 million in 2023. This financial commitment underscores CRISPR's aggressive pursuit of cutting-edge gene-editing technologies, while Xencor focuses on antibody and protein engineering. As these companies continue to innovate, their R&D strategies will be crucial in shaping the future of biotechnology.
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Xencor, Inc.
R&D Insights: How GSK plc and Xencor, Inc. Allocate Funds
argenx SE or CRISPR Therapeutics AG: Who Invests More in Innovation?
Insmed Incorporated vs Xencor, Inc.: Strategic Focus on R&D Spending
Ascendis Pharma A/S vs CRISPR Therapeutics AG: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Ionis Pharmaceuticals, Inc. and CRISPR Therapeutics AG
Who Prioritizes Innovation? R&D Spending Compared for Alkermes plc and CRISPR Therapeutics AG
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Xencor, Inc.
CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Veracyte, Inc. vs Xencor, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: ACADIA Pharmaceuticals Inc. vs Xencor, Inc.
R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Xencor, Inc.